PT - JOURNAL ARTICLE AU - Cristina Helena Rama AU - Luisa Lina Villa AU - Sonia Pagliusi AU - Maria Antonieta Avilla Andreoli AU - Maria Cecilia Costa AU - Patricia Thomann AU - Adhemar Longatto-Filho AU - Jose Eluf-Neto TI - Seroprevalence of Human Papillomavirus 6, 11, 16, and 18 in Young Primiparous Women in Sao Paulo, Brazil AID - 10.1111/IGC.0b013e3181f3c85e DP - 2010 Oct 01 TA - International Journal of Gynecologic Cancer PG - 1405--1410 VI - 20 IP - 8 4099 - http://ijgc.bmj.com/content/20/8/1405.short 4100 - http://ijgc.bmj.com/content/20/8/1405.full SO - Int J Gynecol Cancer2010 Oct 01; 20 AB - Introduction: Data on epidemiology of HPV infection are needed for the development of human papillomavirus (HPV) vaccine recommendations, especially in countries where HPV vaccination is not yet included in public vaccination programs. The aim of this study was to determine the prevalence of serum antibodies to HPV types 6, 11, 16, and 18 and associated factors among young women after birth of the first child.Methods: This cross-sectional study was carried out in a large public maternity hospital in Sao Paulo, Brazil. Three hundred one women aged 15 to 24 years who gave birth to their first child were recruited between 43 and 60 days after delivery. Seroprevalence was performed using a type-specific enzyme-linked immunosorbent assay based on HPV Late protein 1 viruslike particles. The association of seroreactivity with these 4 HPV types with selected demographic and behavioral factors was assessed by Generalized Linear Model analysis.Results: Fifty-eight (19.3%) women (95% confidence interval, 15.0%-24.2%) had antibodies to any of the 4 viruslike particles tested. The overall seroprevalence rates of the HPV types were: HPV16, 9.0%; HPV18, 7.0%; and HPV 6+11, 7.7%, which are targeted by the HPV prophylactic vaccines. In the multivariate analysis, only age (inversely, P = 0.044 for trend) and previous sexually transmitted disease (P = 0.008) were 2 factors independently associated with HPV seropositivity.Conclusions: These data offer additional information on the epidemiology of HPV in a group of young Brazilian women after first delivery and contribute to establish a baseline of HPV seroprevalence against which post-HPV vaccine era seroprevalence can be compared.